BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study
Số trang: 8
Loại file: pdf
Dung lượng: 399.13 KB
Lượt xem: 12
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
BK-UM (CRM197) is a mutant form of diphtheria toxin and a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF). We assessed the safety, pharmacokinetics, recommended dose, and efficacy of BK-UM in patients with recurrent ovarian cancer (OC) or peritoneal cancer (PC), and measured HB-EGF levels in serum and abdominal fluid after BK-UM administration.
Nội dung trích xuất từ tài liệu:
BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study
Nội dung trích xuất từ tài liệu:
BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-inhuman phase-I study
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Ovarian cancer Phase-I study Targeted therapy Diphtheria toxinTài liệu có liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 179 0 0 -
6 trang 171 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 150 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 135 0 0 -
12 trang 103 0 0
-
19 trang 81 0 0
-
17 trang 71 0 0
-
9 trang 48 0 0
-
5 trang 46 0 0
-
9 trang 43 0 0